Table 3.

Comparison of cytogenetic aberrations and NPM1 and FLT3-ITD mutations in patients with AML (n = 1485)




NPM1-mut/FLT3-ITDneg

NPM1-mut/FLT3-ITDpos

NPM1-wt/FLT3-ITDpos

NPM1-wt/FLT3-ITDneg
No.   244   164   148   929  
Unknown, no. (%)   14 (5.7)   12 (7.3)   7 (4.7)   57 (6.1)  
Normal, no. (%)   182 (79.1)  142 (93.4)  76 (53.9)  309 (35.4)  
Abnormal, no. (%)   48 (20.9)   10 (6.6)   65 (46.1)   563 (64.6)  
t(8;21), no.   2   0   3   52  
inv(16)/t(16;16), no.   2   0   5   60  
t(15;17), no.   0  0   11   36  
+8, no.   11   1   12   100  
-7/7q-, no. (%)   5   0   3   114  
-5/5q-, no. (%)   3   0   0   91  
t(6;9), no.   0   0   7   0  
Complex, no.*  4  0   5   176  
-X/-Y, no.   7   2   2   48  
FLT3D835/836, no. (%)  31/204 (15.2)  8/133 (6.0)   9/124 (7.3)   42/772 (5.4)  
MLL-PTD, no. (%)
 
0/126 (0)
 
0/81 (0)§
 
11/73 (15.1)§
 
28/476 (5.9)
 



NPM1-mut/FLT3-ITDneg

NPM1-mut/FLT3-ITDpos

NPM1-wt/FLT3-ITDpos

NPM1-wt/FLT3-ITDneg
No.   244   164   148   929  
Unknown, no. (%)   14 (5.7)   12 (7.3)   7 (4.7)   57 (6.1)  
Normal, no. (%)   182 (79.1)  142 (93.4)  76 (53.9)  309 (35.4)  
Abnormal, no. (%)   48 (20.9)   10 (6.6)   65 (46.1)   563 (64.6)  
t(8;21), no.   2   0   3   52  
inv(16)/t(16;16), no.   2   0   5   60  
t(15;17), no.   0  0   11   36  
+8, no.   11   1   12   100  
-7/7q-, no. (%)   5   0   3   114  
-5/5q-, no. (%)   3   0   0   91  
t(6;9), no.   0   0   7   0  
Complex, no.*  4  0   5   176  
-X/-Y, no.   7   2   2   48  
FLT3D835/836, no. (%)  31/204 (15.2)  8/133 (6.0)   9/124 (7.3)   42/772 (5.4)  
MLL-PTD, no. (%)
 
0/126 (0)
 
0/81 (0)§
 
11/73 (15.1)§
 
28/476 (5.9)
 

The number of patients with individual aberrations adds to a higher number than the absolute number of patients with aberrations because several patients had more than one aberration.

*

Three or more structural or numerical chromosomal aberrations.

P < .01.

P < .001.

§

P < .05.

No. of positive cases/total cases analyzed.

Close Modal

or Create an Account

Close Modal
Close Modal